Cancer medicines
Ibrutinib
Ibrutinib
A BTK inhibitor for selected B-cell blood cancers.
Sources checked · Introductory guide
On this page
How it works
It inhibits BTK to block B-cell survival and growth signals.[3]
Where it is used
Used in selected CLL/SLL and Waldenström macroglobulinemia settings.[1]
Key safety points
Monitor bleeding, infection, rhythm and blood pressure. Disclose anticoagulants and procedures; seek prompt advice for bleeding, palpitations or fever.[2]
Questions for your care team
- How are bleeding, rhythm risks and medicine management around procedures handled?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Ibrutinib (opens in a new tab)
- MedlinePlus · Ibrutinib (opens in a new tab)
- NCI Drug Dictionary · Ibrutinib (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.